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Abstract
Background
The incidence of Clostridium difficile infection (CDI) has been increasing in
communities and healthcare associated settings in the last 25-50 years. Clostridium difficile is a
Gram-positive bacteria found in the large bowel or colon that causes mild to severe intestinal
conditions and sometimes death. The primary risk factors for development of CDI include
healthcare exposure and recent antimicrobial use. The purpose of this study is to compare risk
factors associated with CDI occurring in the Community to those associated with Healthcare
Facility Associated CDI in the metro Atlanta population from September 1, 2009 – April 30,
2011.
Methods
Patients were identified through C. difficile surveillance program of the Georgia
Emerging Infections Program (EIP). Prospective, population based, laboratory based surveillance
for all positive C. difficile cases in the Georgia Health District 3 (HD3). Due to high volume of
positive CDI, a stratified random 1:3 sampling scheme is used and cases are stratified by age and
gender. Identified sampled cases undergo a retrospective Case Report Form completion and are
classified in to three classifications: Community Associated (CA), Community Onset-Healthcare
Facility Associated (CO-HCFA), and Healthcare Facility Onset (HCFO). An additional 1:10
sampling occurs for HCFO cases. Due to the sampling scheme, for this analysis CO-HCFA and
HCFO cases were combined to make a Healthcare Facility Associated (HCFA) classification.
Using SAS, a logistic regression analysis was performed to compare the associated risks between
CA and HCFA classifications.
Results
The rate of CDI in the HD3 counties in Georgia is 84 per 100,000. The median age of
infection is 63 and the age range in this study is 1 to 102 years old. CA cases represented 38% of
the sampled population. CDI cases 65 and older were more likely to have a Healthcare
association compared to CA-CDI cases (p <0.01). HFCA-CDI cases were more likely to be
exposed to the following antibiotics Cephalosporins, Metronidazole, and Vancomycin ( all p
values <0.01). In addition, HCFA-CDI cases were more likely to have the following underlying
conditions Cardiovascular, Neurological, Tumors, Other Chronic Conditions, and Diabetes (all p
values <0.0001) compared to CA-CDI Cases. HCFA-CDI cases had individuals that had two or
more underlying conditions and had more individuals that were taking two or more antibiotics 14
days prior to a positive stool culture compared to CA-CDI cases (both chi square <0.0001).
Conclusion
CDI is prevalent in the metro Atlanta population and this study identifies the risk factors
that are associated with Community Associated Cases and Healthcare Facility Associated Cases.
Based on this population sample, antibiotics use and underlying conditions appear to be
significant factors in HCFA-CDI cases compared to CA-CDI cases. This study supports
literature about CDI and antimicrobial use and looks further in to the role underlying conditions
play as a risk factor for HCFA-CDI cases.
ii

KEY WORDS
Public Health, Clostridium difficile, healthcare associated infections, community associated
infections, antibiotics, underlying conditions, age, Atlanta

iii

Comparison of Risk Factors for Clostridium Difficile Infection
Among Community Associated Cases and Healthcare Facility
Associated Cases, September 2009- April 2011
by
Zirka Thompson
April 04, 2012

Approved:
Dr. Lisa Casanova
Committee Chair
Dr. Frances McCarty
Committee Member
Date: January 2011

A Thesis Submitted to the Graduate Faculty
of Georgia State University in Partial Fulfillment
of the Requirements for the Degree
Masters of Public Health
Atlanta, Georgia
iv

Acknowledgements
I would like to sincerely t hank my thesis committee members, Dr. Casanova and Dr. McCarty.
In addition, I would like to thank those who helped me at work: Dr. Farley, Andrew Revis, Amy
Holt and Wendy Baughman. This process would not have been possible without their guidance,
feedback, and insight. I would also like to thank the Georgia Emerging Infections Program and
the Centers for Disease Control and Prevention for using their data.
Also, to my family and friends for their support and encouragement.

v

Statement
I hereby certify that, if appropriate, I have obtained and attached hereto a written permission
statement from the owner(s) of each third party copyrighted matter to be included in my thesis,
dissertation, or project report, allowing distribution as specified below. I certify that the version I
submitted is the same as that approved by my advisory committee.
I hereby grant to Georgia State University or its agents the non-exclusive license to archive and
make accessible, under the conditions specified below, my thesis, dissertation, or project report
in whole or in part in all forms of media, now or hereafter known. I retain all other ownership
rights to the copyright of the thesis, dissertation or project report. I also retain the right to use in
future works (such as articles or books) all or part of this thesis, dissertation, or project report.

Zirka THOMPSON__________________________
Signature of Author

vi

Table of Contents
CHAPTER I ...................................................................................................................................2
Introduction ..................................................................................................................................2
Study Question .........................................................................................................................5
CHAPTER II ..................................................................................................................................6
Literature Review .........................................................................................................................6
Background...............................................................................................................................6
Clinical Manifestation ..............................................................................................................6
Epidemiology ...........................................................................................................................7
Risk Factors ..............................................................................................................................9
Residence ................................................................................................................................12
CHAPTER III ..............................................................................................................................15
Methods ......................................................................................................................................15
Patient Selection .....................................................................................................................15
Statistical Analysis .................................................................................................................16
IRBs ........................................................................................................................................17
CHAPTER IV...............................................................................................................................19
Results ........................................................................................................................................19
CHAPTER V ................................................................................................................................25
Discussion ..................................................................................................................................25
Conclusion ..............................................................................................................................29
WORK CITED .............................................................................................................................30
POWER POINT PRESENTATION ..........................................................................................33
APPROVED DOCUMENTS ......................................................................................................54

vii

CHAPTER I
Introduction
The incidence of Clostridium difficile infection (CDI) has been increasing in
communities and healthcare associated settings in the last 25-50 years. Clostridium difficile is a
Gram-positive bacteria found in the large bowel or colon that causes mild to severe intestinal
conditions and sometimes death. Exposures to healthcare settings and antibiotic use have most
often been cited as risk factors for CDI. In recent years, CDI has become more frequent, more
severe, and more difficult to treat. Each year tens of thousands of people in the United States get
sick from C. difficile, including some otherwise healthy people who are not hospitalized or
taking antibiotics (Kyne, Hamel, Polavaram, & Kelly, 2002). Mild illness caused by CDI may
resolve by discontinuing antibiotics. Severe symptoms require treatment with an antibiotic
targeting C. difficile (Owens, Donskey, Gaynes, Loo, & Muto, 2008). The most common
symptoms of mild to moderate C. difficile infection are watery diarrhea occurring three or more
times a day for two or more days and mild abdominal cramping and tenderness (McDonald et al.,
2005). More severe CDI can lead to colitis, pseudomembranous colitis, and death (Kyne et al.,
2002).
Pathogenic strains of C. difficile produce two distinct toxins. Toxin A is an enterotoxin,
and toxin B is a cytotoxin. Both are high-molecular weight proteins capable of binding to
specific receptors on the intestinal mucosal cells. (Nusrat et al., 2001). CDI occurs from a
disturbance of the normal bacterial flora of the colon, acquisition of C. difficile, and the release
of toxins that cause mucosal inflammation and damage (Gronczewski et al., 2012). Antibiotic
therapy is the key factor that alters the colonic flora (Owens et al., 2008). Acquisition occurs via
the fecal – oral route (Jarvis, 1996) leading to either asymptomatic colonization or clinical
disease. C. difficile forms heat-resistant spores that can persist in the environment for several
2

months to years. The hand picks up the bacteria from a surface that has minute amounts of fecal
contamination and the bacterium finds its way to the mouth via touch, food, etc. However, unlike
many other bacteria, C. difficile spores can survive in both hot and cold temperatures and is
resistant to the action of many chemicals, including the alcohol-based hand sanitizers which
makes killing this bacteria difficult (McDonald, 2005). Normal gut flora resists colonization and
overgrowth with C. difficile. Transmission of C. difficile occurs primarily in healthcare facilities,
where the environmental contaminations by C. difficile spores and exposure to antimicrobial
drugs are common. Antibiotic use suppresses the normal flora allowing proliferation of C.
difficile (Gronczewski et al., 2012; McDonald, 2005). However, C. difficile is no longer limited
to healthcare environments and is increasing in the community in both healthcare and nonhealthcare exposed populations (Henrich, Krakower, Bitton, & Yokoe, 2009).
The primary risk factors for development of C. difficile include healthcare exposure and
recent antimicrobial use. Additional risk factors for acquisition include age greater than 65 and
severe underlying illness. Healthcare exposure can occur from cross contamination situations. As
C. difficile spores are dispersed by fecal matter, patient, staff, and environmental hygiene is vital
(Jarvis, 1996). Staff cannot always avoid coming in contact with C. difficile spores and the main
agent of transmission is often hands. In addition, another vehicle for transmission is hospital,
long term care facility, or nursing home toilets. Environmental cleaning is important in
healthcare facilities and the use of special disinfectants are needed because C. difficile spores are
hardy and can survive for several months and are not killed by many cleaning agents alone
(McDonald, 2005).
For most healthy people, C. difficile does not pose a health risk. The elderly, those with
other illness, or taking antibiotics are at greater risk of infection. Using antibiotics increases the
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chance of developing C. difficile infection. Antibiotics alter the normal levels of protective
bacteria found in the intestines and colon. When the balance of the normal flora in our intestines
and colon has been disrupted, C. difficile bacteria have the chance to thrive and produce toxins
(Warny et al., 2005). These toxins cause inflammation of the bowel and cause mild to severe
diarrhea. Age is also a risk factor for the development of disease. People ages 65 years and older
are 10 times more likely to become infected with C. difficile compared to those less than 65
(Lambert, Dyck, Thompson, & Hammond, 2009).
C. difficile is very common in the Atlanta, Georgia metropolitan population based upon a
population-based surveillance system established by the Georgia Emerging Infections Program
in 2009. C. difficile cases are identified through toxin positive stool cultures, identified in
hospital or reference laboratories. Eligibility requirements include being a resident of Health
District 3 and being over 1 year of age on collection date. Population-based surveillance allows a
comparison of Community Associated and Healthcare Facility Associated cases of CDI.
Although risk factors for healthcare associated infection have been established, risk factors for
community onset disease are less well understood. Active, population-based surveillance for CDI
provides longitudinal study of the incidence rates of CDI Unlike many other studies of CDI,
prospective, population-based surveillance is not restricted to outbreak investigation but rather,
all reported cases between September 2009 and April 2011 occurring in Atlanta Health District 3
can be analyzed.
CDI surveillance data collected from September 1, 2009 to April 30, 2011 from 8
counties in metropolitan Atlanta, Georgia (Clayton, Cobb, Dekalb, Douglas, Gwinnett, Fulton,
Newton, and Rockdale) were utilized for this project known as Health District 3 (HD3). An
analysis was conducted to compare risk factors associated with C. difficile infections occurring in
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the Community to those associated with Healthcare Facility Associated CDI Cases. The
objectives of this investigation were to examine the antibiotic use and underlying conditions
associated with CDI. In addition, age over 65 is a risk factor, so age will be considered in the
analysis while comparing the two groups. This analysis will assist in better understanding CDI in
a described population and determine whether there are differences between Community
Associated infections and Healthcare Facility Associated infections.

5

CHAPTER II
Literature Review
Clostridium difficile Background
Clostridium difficile was first described in 1935 as part of the intestinal microflora in
neonates. Although the severe form of C. difficile disease was first discovered in 1893, the
pathogen was not actually identified as the causative agent of human disease until 1978
(McDonald et al). C. difficile is an anaerobic, spore-forming, toxigenic bacteria that is the most
commonly recognized cause of infectious nosocomial diarrhea and one of the most common
healthcare-associated pathogens (Campbell et al., 2009). C. difficile infection (CDI) is a toxinmediated intestinal disease, and extra-intestinal manifestations are rare. C. difficile is recognized
as the main cause of infectious diarrhea that develops in patients after hospitalization and
antimicrobial treatment (Thomas et al). The association between antimicrobial therapy and CDI
is very strong, as C. difficile can only colonize the gut if the normal intestine microbiota is
disturbed or absent (Gronczewski et al). A case of C. difficile incidence (CDI) is defined as a
positive toxin or nucleic acid C. difficile assay (Cohen et al., 2010). C. difficile can be detected in
stool specimens.

Clinical Manifestation
The clinical manifestations of infection with toxin-producing strains of C. difficile range
from asymptomatic carriage, mild or moderate diarrhea, to fulminant and sometimes fatal
pseudomembranous colitis (Barbut et al., 1996; Cohen et al., 2010). Several studies have shown
that 50% or more of hospital patients colonized by C. difficile are asymptomatic carriers,
possibly reflecting natural immunity (Kyne et al., 2002). Symptoms of CDI usually begin soon
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after acquisition, with a median time to onset of symptoms of 2-3 days(McFarland, Clarridge,
Beneda, & Raugi, 2007).
C. difficile diarrhea may be associated with the passage of mucus or occult blood in the
stool, but melena or hematochezia are rare. Fever, cramping, abdominal discomfort, and a
peripheral leukocytosis are common but found in fewer than half of patients (Cohen et al., 2010).
C. difficile ileitis or pouchitis has also been rarely recognized in patients who have previously
undergone a total colectomy (McDonald et al., 2005). Patients with severe disease may develop a
colonic ileus or toxic dilation and present with abdominal pain and distension but with minimal
or no diarrhea. Complications of severe C. difficile colitis include dehydration, electrolyte
disturbance, hypoalbuminemia, toxic megacolon, bowel perforation, hypotension, renal failure,
systemic inflammatory response syndrome, sepsis, and death (Cohen et al., 2010).

Epidemiology
In 2002, the University of Pittsburgh Medical Center in the United States reported an
increase of severe CDI, which focused attention on rising rates of CDI in Canada, the United
States, and Europe (Henrich et al). According to McDonald et al, in 2006, the CDI discharge
diagnosis rates in U.S hospitals exceeded 300,000 cases per year, which was an increase from
less than 150,000 in 2000. It is currently estimated that there are approximately 500,000 cases of
CDI per year in hospitals and long-term care facilities based on annual data from the State of
Ohio in 2006 (Ohio Department of Health).
McDonald et al and others hypothesize that patients are exposed to C. difficile spores
most often through contact with the hospital environment or health care workers And after taking
an antibiotic, the person develops CDI if he/she acquires a toxigeneic C. difficile strain and lacks
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an effective antibody response to the toxins. Lack of preexisting antibodies or timely antibody
production may result in symptomatic CDI. Alternatively, if antitoxin antibodies are present or
produced in a timely fashion, the patient may become asymptomatically colonized with C.
difficile. Also, acquisition of a non-toxigenic C. difficile strain may lead to asymptomatic
colonization. Colonized patients have been shown to be protected from CDI.
A veterinary model by Asha et al helps to understand the pathogenesis of C. difficile in
the intestine. C. difficile colonizes the intestine (colon) after disruption of the normal intestinal
flora. However the roles of adhesion and biofilm production involved in the pathogenesis of C.
difficile are unknown. The bacterial cells are free to begin with and then attach to host cells.
Toxigenic strains produce toxin A and toxin B. Toxin B binds to the apical side of the cell and
after internalization causes cytoskeletal changes that result in disruption of the tight junction,
loosening the epithelial barrier. The disruption of the junction enables toxins A and B to cross
the mucosal surface. Both toxins are cytotoxic and induce the release of various
immunomodulatory mediators resulting in inflammation and the accumulation of neutrophils.
The local inflammatory effects of CDI result in the formation of “volcano-like” lesions which
can lead to pseudomembranes that form from the destruction of the intestinal cells and
leukocytes.
C. difficile spores
C. difficile forms spores that are highly resistant to desiccation, chemical and extreme
temperatures. Spores frequently contaminate the environment around patients with CDI,
potentially persisting for months and even years (Ausiello C. M et al). More recently according
to Fawley W.N et al, a study on cleaning products has shown spores can survive in the
temperatures and disinfectant treatment of typical hospital laundering cycles and can cross-
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contaminate bed linens during a wash cycles. In vitro exposure of C. difficile strain to subinhibitory concentrations of non-chlorine-based cleaning agents significantly increased
sporulation capacity, an effect that is not generally seen with chlorine-based cleaning agents.
Working-strength concentrations of five different cleaning agents inhibited the growth the C.
difficile in vitro but only chlorine-based cleaning agents inactivated C. difficile spores.
Risk Factors
A number of factors that are known to increase risk for CDI are discussed below.
Antibiotics
Historically, the antimicrobials most commonly associated with CDI in well-conducted
studies are clindamycin, penicillins, and cephalosporins. The increase use of fluoroquinolones
among both inpatients and outpatients is now a common risk factor for CDI. The use of
antibiotics are common and many studies have established the risk of antibiotics exposure
associated with CDI (McDonald et al., 2005).
The negative effect of antibiotics on the gut flora is a risk factor for CDI. Patients are
generally resistant to CDI if their normal gut flora is unaltered by antibiotics. Once antibiotic
treatment begins, infection with a C. difficile strain that is resistant to the antibiotic is more likely
while the antibiotic is being administered owing to the presence of the antibiotic on the gut.
When the antibiotic treatment stops, the levels of the antibiotic in the gut diminish rapidly, but
the microflora remains disrupted for a variable period of time, depending on the antibiotic.
During this time period, patients can be infected with either resistant or susceptible C. difficile.
After the microflora recovers from the antibiotic treatment, a process that may take months,
colonization resistance to C. difficile is restores (Asha et al).
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A number of recent studies have investigated the risks associated with various antibiotics
in the development of CDI. Olsen et al reported that 96% of patients with symptomatic C.
difficile infection had received antimicrobials within the 14 days before the onset of diarrhea and
that all had received an antimicrobial within the previous 3 months.
Loo et al performed a case-control study of 237 patients with CDI in 12 Quebec
hospitals. This study found an odds ratio of 3.9 for receipt of fluoroquinolones in the
development of CDI and an odds ratio of 3.8 for cephalosporins. Antibiotic resistance testing
demonstrated widespread fluoroquinolone resistance in the infecting CDI strain. It was proposed
that frequent fluoroquinolone use contributed to the spread of the CDI NAP1/o27 strain within
Quebec.
Other groups have similarly proposed that outbreaks in their institutions were facilitated
by an increase in fluoroquinolones usage. Muto et al. describe an outbreak of CDI at a teaching
hospital in Pittsburg following a change in the antibiotic formulary from ciprofloxacin to
levofloxacin. Pepin et al analyzed the risk associated with different antibiotics for the
development of CDI in Quebec and found fluoroquinolones to confer the highest risk and, due to
their common usage, to also account for the highest population attributable fraction (36%).
Gaynes et al., in Atlanta, attributed an outbreak of CDI at a long term care facility to the
switch in their formulary from levofloxacin to gatifloxacin which has an extended spectrum for
anaerobic bacteria. This study was conducted to determine the cause of an increase rate of CDI
in a long term care facility (LTCF). CDI cases were analyzed from October 2001 through June
2002. Cases were identified from positive enzyme immunoassay for C. difficile toxin A. The
increase coincided with a formulary change from levofloxacin to gatifloxacin. A case-control
study used randomly selected control subjects, a variety of risk factors, logistic regression
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analysis demonstrated associations between CDI and use of clindamycin and gatifloxacin;
gatifloxacin being associated with an increase of CDI during the outbreak period. In conclusion,
this study was able to associate the outbreak with a formulary change from levofloxacin to
gatifloxacin. The rates of CDI declined after a switch back to levofloxacin, concomitant with
other control measures.

Underlying Condition
It was known previously that immunosuppression predisposes an individual to develop
severe CDI. There have been, however, few controlled studies of CDI risk in HIV infection.
Sanchez reviewed data from the Adult/ Adolescent Spectrum of HIV Disease (ASD) Project and
found that C. difficile was the most commonly isolated bacterial cause of diarrhea in individuals
with HIV during 1992-2002, accounting for 598 of 1115 (53.6%) bacterial agents identified. This
high CDI risk is likely to be the result of frequent prophylactic and therapeutic antibiotic courses
in HIV-infected individuals as well as their frequent visits to healthcare facilities.
A study by Nylund et al suggests an increase in CDI infection among hospitalized
children, especially those hospitalized with medical conditions such as inflammatory bowel
disease and immunosuppression. Also at risk are those hospitalized with conditions that require
antibiotic administration.

Age
C. difficile is more common in elderly people, and old age may promote susceptibility to
colonization and disease (Asha et al). While infants and young children frequently harbor C.
difficile and its toxins, clinical infection is uncommon. More recently there have been reports of
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populations affected by C. difficile that would normally be considered low risk. These
populations include young healthy persons not exposed to a hospital environment or
antimicrobial therapy and young pregnant women in the peripartum setting.
There is a high incidence and increased mortality among older patients that is attributed
to the failure of these individuals to create an effective immune response when first exposed to
the C. difficile toxins. This lack of immune response has also been associated with higher rates of
recurrent disease (Kyne et al).

Residence
Community Associated
The Morbidity and Mortality Weekly Report of December 2005 highlighted concerning
reports of severe CDI in individuals previously considered at low risk. The CDC investigated
cases reported in peripartum women and cases of community acquired CDI. Voluntary
participants were requested to report peripartum CDI cases nationally through epi-X, and locally
in Pennsylvania and New Jersey for community acquired CDI during May and June of 2005. 10
peripartum CDI cases and 23 community acquired CDI cases were reviewed. Eight of the 33
patients had no documents exposure to antibiotics in the three months before onset of disease.
Three of the eight had close contact with someone with a diarrheal illness and two isolates were
available for strain typing, both stools detected excess toxins A and B.
In the United Kingdom Dial et al examined the development of community acquired
CDI. This large population case-control study examined gastric acid suppressive agents as a risk
factor for the development of CDI. The authors identified 1233 patients with CDI who had not
been hospitalized in the year prior to diagnosis and were therefore considered to have community
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acquired CDI. Of the 833 patients who were diagnosed with the infection based on a positive
toxin assay, only 284 (34%) had a documented history of antibiotic use within 90 days prior to
diagnosis. These findings were in contrast with nosocomial CDI, for which the vast majority of
patients have a history of recent antibiotic use.

Health Care Facility Associated
According to Miller et al hospitalization and exposure to a healthcare facility is a risk
factor for the acquisition of CDI for many reasons. Healthcare exposure multiples the risk of CDI
because it increases the likelihood of exposure to antibiotics, spore-contaminated environments,
inadequate hand hygiene by health care workers and a highly susceptible elderly population of
patients that may be hospitalized.
A study by Archibald et al addresses the rates of CDI in hospital settings. The authors
reviewed C. difficile associated disease data from intensive care units (ICU) and hospital wide
surveillance components of the National Nosocomial Infections Surveillance system hospitals
during 1987- 2001. ICU CDI rates increased significantly in hospitals with more than 500 beds
(p<.01) and correlated with the duration of ICU stay. CDI was highest in general hospitals versus
other facility types, and the rates were significantly higher in winter months versus non-winter
months (p<0.1).
Campbell et al described the disease burden and mortality rate of healthcare-onset CDI,
suggesting that the incidence and severity of CDI is increasing in healthcare-related
establishments. In 2006, active public reporting of healthcare-onset CDI was mandated for all
Ohio hospitals and nursing homes. Incident rates were determined and stratified according to
healthcare facility characteristics and death certificates that listed CDI were analyzed. There
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were a total of 14,329 CDI cases reported, including 6,376 at 210 hospitals. The rate for initial
cases was 6.4-7.9 cases/10,000 patient-days for hospitals and 1.7-2.9 cases/10,000 patient-days
for nursing homes. Death certificates for 2006 listed CDI among the causes of death for 893
Ohio residents; between 2000-2006 this number increased more than 4-fold.
A case control study conducted in 1993 by Barbut et al looked at determining the
prevalence of C. difficile in stool specimens of hospitalized patients sent to hospital microbiology
laboratories, to assess the relationship between serotypes and toxigenicity of the strains isolated,
and evaluate the clinical data. The presence of C. difficile was systematically investigated from
January 1993- July 1993 by looking at 3921 stool samples sent for stool cultures to 11 French
hospital microbiology laboratories. The prevalence in this population was compared with that of
a group of 220 random hospital controls matched for age, department, and length of stay. Stool
cultures from controls were collected by laboratory personnel for the purposes of the study;
serotype and toxin production of the strains were determined and compared. Overall the
prevalence of C. difficile in the cases were two times more than in the control group, and
approximately 4 times as high in diarrheal stools compared to normally formed stools from
controls. Strains were more frequently toxigenic in loose stools than those isolated from
normally formed stools. Serotype C was more commonly found in patients, older than 65 years
of age and those suffering from severe disabling disease, who had been treated with antibiotics
and hospitalized for more than 1 week.
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CHAPTER III
Methods
Patient Selection
Patients were identified through the Clostridium difficile Surveillance Program of the
Georgia Emerging Infections Program (EIP). Since September of 2009 the GA EIP has
performed prospective, population-based, laboratory-based surveillance for all the positive C.
difficile cases in Georgia Health District 3 (HD3), the 8-county Atlanta metropolitan area. All
residents aged one year and older in the surveillance areas from whom a positive C. difficile
toxin enzyme immunoassay (EIA) or positive C. difficile nucleic acid assay (e.g PCR) from
human stool or an ileostomy specimen was obtained were eligible for investigation. Clinical
laboratories in the surveillance area, on a monthly basis, will provide a line list of positive C.
difficile toxin assay test results and patient identifying information. Each positive assay result
was cross-checked with a dataset containing previous line lists positive C. difficile toxin tests to
determine if episodes were a duplicate, recurrent, or incident CDI case. A case of CDI was
defined as a positive C. difficile test on an incident stool specimen. Cases with a positive stool
specimen for C. difficile greater than 8 weeks after the last positive specimen were considered a
new case (Baughman et al).
Study personnel retrospectively reviewed medical records using a standardized case
report form (CRF) to abstract data on demographics, clinical characteristics, and outcomes.
Cases were classified in to 3 categories: Healthcare Facility Onset (HCFO), Community Onset
Healthcare Facility Associated (COHCFA), or Community Associated (CA). HCFO is defined as
a case with the initial C. difficile positive specimen collected greater than four calendar days after
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admission to a healthcare facility (i.e. acute care hospital, long-term care acute hospital, long
term care facility). Community onset cases with an overnight stay at a healthcare facility in the
twelve weeks prior to initial positive C. difficile result were classified as CO-HCFA. Cases with
community onset without a documented overnight stay in a healthcare facility in the twelve
weeks prior to initial positive specimen collection were classified as CA (Baughman et al).
Due to the high volume of positive C. difficile assays present in this population, a
stratified random sampling scheme was used and cases were stratified by age and gender except
for the youngest age group of males and females 1-17. All cases occurring in those 1-17 years of
age were included in the analysis. For the remaining groups, male and females 18-44, 45-64,
>65, only 1:3 CDI cases were sampled and a CRF was completed on those sampled (except
September 2009 and October 2009). In the classification of HCFO, 1:10 cases were randomly
selected for CRF completion (Baughman et al). Figure 1 represents a breakdown of the case
selection used for analysis.
Due to the sampling scheme, for this analysis the classifications COHCFA and HCFO
were combined to make a Healthcare Facility Associated (HCFA) category. Therefore the
outcomes being described are CA and HCFA. The underlying conditions and antibiotics were
grouped to form classifications for analysis (see appendix 1 and 2 for table representing the
combinations).
Statistical Analysis
The study period for this analysis was from September 1, 2009 through April 30, 2011.
Statistical analyses were performed using SAS, version 9.2 (SAS Institute, Cary, NC). A logistic
regression was performed to identify risk factors significantly associated with the specified
16

outcomes. In addition, a chi squared analysis was then performed to evaluate the impact of being
on no, one, or two or more antibiotics versus. The same analysis was performed for underlying
conditions to see if a patient with CDI was more likely to have none, one, or two or more
underlying conditions. Odds Ratios were also calculated to compare HCFA-CDI cases to CACDI cases when specifically looking at the relationships between either no antibiotics or no
underlying condition compared to an individual antimicrobial classification or underlying
condition group.
IRB
This study was approved by the Georgia State University (Protocol #H12310) and Emory
University’s (Protocol #5558.0) IRBs, and the VA Research and Development Committee
(Protocol #16622).
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Figure 1: Flow Chart demonstrating the sample method used for this study.
All CDI Incident Cases in HD3
Catchment
(September 1, 2009 –
April 30, 2011)
N = 5244
September 1, 2009 –
October 31, 2009
NO 1:3 Sample
N1= 453

November 1, 2009 –
April 30, 2011
1:3 Sampled
N2 = 1770

HCFO1

COHCFA1

CA1

HCFO2

COHCFA2

CA2

N=214

N=87

N= 134

N= 724

N= 326

N= 704

HCFO1
1:10
Sample
N=9

COHCFA1

CA1

COHCFA2

N=87

N= 134

HCFO2
1:10
Sample
N=56

HCFO1+2
N=65

COHCFA1+2
N=413

HCFA
N=477

N= 704

N= 326

CA1
N= 134

Total Sampled
N= 1314

CA2

CA2
N= 704

CA1+2
N= 837
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CHAPTER IV
Results
Between September 1, 2009 and April 30, 2011, 5244 incident cases were identified by
the GA EIP surveillance project. The incident rate of CDI in the Metro Atlanta population was
84 cases per 100,000 calculated using all incident cases in 2010 compared to 2010 census data.
The median age was 63, with ages ranging from 1 to 102, and 61% of the cases studies were
female.
Demographics of cases included in the study are shown in Table 1. In addition, 38% of
the cases had no healthcare facility association and a majority of this sample was White/ NonHispanic (48%). Looking at the CA cases, the column percents show a similar distribution
among age groups where in the CO-HCFA and HCFO the distribution of cases increase with age.
TABLE1 Description of Cases, September 2009 – April 2011

CA
n=837
(38%)
(col %)

CO-HCFA
n=413
(19%)
(col %)

HCFO
n=938
(43%)
(col %)

Total (%)

1-17
18-44
45-64
65+

208 (25)
179 (21)
237 (28)
214 (26)

30 (7)
65 (16)
103 (25)
215 (52)

15 (1.6)
81 (8.6)
231 (25)
611 (65)

253 (12)
325 (15)
568 (26)
1039 (47)

Male
Female

315 (38)
523 (62)

172 (42)
241 (58)

371 (40)
567 (60)

855 (39)
1330 (61)

308 (64)
151 (32)
19 (4)
9
351

228 (63)
114 (32)
18 (5)
6
47

516 (59)
344 (39)
15 (2)
12
51

1050 (48)
607 (28)
52 (2)
27 (1)
449 (21)

Age

Sex

Race/ Ethnicity
White/NH
Black/NH
Hispanic
Other
Unknown
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After the additional 1:10 HCFO sample, the case study population size reduced to 1314.
Of the 938 HCFO cases, only 65 CRFs were completed due to the sampling method. Completed
HCFO cases were combined with the CO-HCFA cases to make a HCFA-CDI group. Table 2
represents a description of the 1314 cases considered for analysis. The age group 65 years and
older are significantly more likely to have a HCFA-CDI compared to CA-CDI group (p<0.01).
TABLE 2 Univariate Descriptions of
Demographics
CA (reference)
n=837

HCFA
n=477

p-value

Age
1-17 (reference)
18-44
45-64
65+

208
179
237
213

30
72
120
255

0.0013

Male (reference)
Female

314
523

198
280

0.5095

Race/ Ethnicity
White/NH (reference)
Black/NH
Hispanic

307
151
19

266
136
18

0.1979
0.0448

Sex

Of the antibiotics that were examined, a univariate chi square analysis was performed to
determine which antibiotic classifications were more of a risk factor for the HCFA-CDI group
compared to the CA-CDI group (Table 3). Using no antibiotic exposure 14 days prior to stool
collection as a reference group, fluoroquinolones, cephalosporins, and Vancomycin were
significantly associated with the HCFA-CDI group compared to the CA-CDI group (p values
<0.01). Among the underlying condition groups reviewed, a univariate chi square analysis
determined that HIV/AIDS, cardiovascular disorders, neurological disorders, other chronic
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conditions, and diabetes were significantly more associated with HCFA-CDI cases compared to
CA – CDI cases.
TABLE 3 Univariate Analysis of Antibiotics
Antibiotics
None
Fluoroquinolones
Cephalosporins
Metronidazole
Vancomycin
Penicillins & Carbopenems
Clindamycin
Macroloids

CA
(%)
395 (47)
50 (7)
58 (7)
64 (8)
18 (2)
76 (9)
26 (3)
23 (3)

HCFA p-value
(%) (chi sq)
185 (39) 0.0032
100 (21) <0.0001
60 (13) 0.0006
55 (12)
52 (11) <0.0001
48 (10)
6 (1)
20 (4)

TABLE 4 Univariate Analysis of Underlying Conditions
Underlying
Conditions
None
HIV/AIDS
Gastrointestinal
Cardiovascular
Neurological
Tumors
Other Chronic
Diabetes

CA
(%)
434 (52)
21 (3)
112 (13)
38 (5)
37 (4)
54 (6)
118 (14)
81 (10)

HCFA
(%)
73 (15)
25 (5)
57 (12)
106 (22)
84 (18)
47 (10)
211 (44)
129 (27)

p-value
(chi sq)
<0.0001
0.0096
<0.0001
<0.0001
<0.0001
<0.0001

An array function in SAS was used to determine the number of cases that were taking
antibiotics 14 days prior to a positive stool or the number of underlying conditions an individual
had. More HCFA-CDI cases (8%) were taking two or more antibiotics compares to CA-CDI
cases (6%). In addition, there were more HCFA-CDI cases (16%) that had two or more
underlying conditions compared to the CA-CDI group (9%).
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TABLE 5 Logistic Regression of Antibiotics

Risk Factors
Antibiotics
None (reference)
Fluoroquinolones
Cephalosporins
Metronidazole
Vancomycin
Penicillins & Carbopenems
Clindamycin
Macroloids
Other
Unknown

CA (reference)

HCFA

p-value

395
27
23
41
13
60
25
17
118
116

185
44
28
41
32
35
5
15
55
36

0.0392
0.0041
0.0026
0.0008
0.0959
0.5603
0.1585
0.4135
0.6549

TABLE 6 Logistic Regression of Underlying Conditions
Risk Factors
Underlying Conditions
None (reference)
HIV/AIDS
Gastrointestinal
Cardiovascular
Neurological
Tumor
Other Chronic
Diabetes
Unknown

CA (reference)

HCFA

p-value

434
14
79
8
22
35
83
81
62

73
9
29
24
32
30
126
129
8

0.0448
0.0219
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.9035

A multivariate logistic regression was then used to determine the difference between the
HCFA-CDI group compared to the CA-CDI group among the different risk factors (reference
tables 5 and 6). The HCFA-CDI group was significantly more likely to be taking the following
antibiotics 14 days prior to a positive stool collection: Cephalosporins, Metronidazole, and
Vancomycin (p <0.01) compared to no antibiotic use the CA-CDI group. The HCFA-CDI group
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was also significantly more likely to have the following underlying conditions, Cardiovascular,
Neurological diseases, Tumor, Other Chronic diseases, and Diabetes compared to no underlying
condition in the CA-CDI group.
TABLE 7 Odds Ratio of Demographic
Risk Factor
Age

Odds Ratio (95% Wald CI)
1-17 (reference)
18-44
45-64
65+

1
1.7 (0.959, 2.896)
1.5 (0.877, 2.587)
2.4 (1.414, 4.193)

Male (reference)
Female

1
0.9 (0.682, 1.209)

White N/H (reference)
Black N/H
Hispanic

1
1.2 (0.889, 1.763)
2.2 (1.006, 4.996)

Sex

Race Ethnicity

TABLE 8 Odds Ratio of Antibiotics
Risk Factor
Antibiotics

Odds Ratio (95% Wald CI)
None (reference)
Vancomycin
Cephalosporin
Metronidazole
Fluoroquinolones
Macroloids
Penicillins & Carbopenems
Clindamycin

1
3.7 (1.716, 7.838)
2.8 (1.382, 5.576)
2.3 (1.347, 4.089)
1.9 (1.032, 3.497)
1.9 (0.785, 4.410)
1.6 (0.922, 2.704)
0.7 (0.246, 2.136)
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TABLE 9 Odds Ratio of Underlying Conditions
Risk Factor
Underlying Conditions

Odds Ratio (95% Wald CI)
None (reference)
Cardiovascular
Other Chronic
Diabetes
Neurological
Tumors
HIV/AIDS
Gastrointestinal

1
10.9 (4.498, 26.805)
6.2 (4.068, 9.367)
5.4 (3.484, 8.251)
3.9 (2.006, 7.556)
3.6 (1.978, 6.469)
2.6 (1.022, 6.678)
1.9 (1.095, 3.200)

An odds ratio was also calculated through the logistic regression and the outputs are
viewed in tables 7, 8, and 9. Table 7 shows that the HCFA-CDI group was 2.4 times more likely
to be 65 or older than the CA-CDI group (C.I 1.414, 4.193). The HCFA-CDI group was also 3.7
times more likely to be taking Vancomycin (C.I 1.716, 7.838), 2.8 times more likely to be taking
Cephalosporins (C.I 1.382, 5.576), 2.3 times more likely to be taking Metronidazole (C.I 1.347,
4.089), and 1.9 times more like to be taking Fluoroquinolones (C.I 1.032, 4.410) than the CACDI group (table 8). The HCFA-CDI group is significantly more likely to have an underlying
condition compared to the CA-CDI group (table 9). The HCFA-CDI group is 10.9 times more
likely to have a cardiovascular disorder (C.I 2.298, 26.805), 6.2 times more likely to have
another Chronic disorder (C.I 4.068, 9.367), 5.4 times more likely to have Diabetes (C.I 3.484,
8.251), 3.9 times more likely to have a Neurological disease (C.I 2.006, 7.556), 3.6 times more
likely to have a Tumor (1.978, 6.469), 2.6 times more likely to have HIV/AIDS (C.I 1.022,
6.678), and 1.9 times more likely to have a Gastrointestinal disorder (C.I 1.095, 3.200) compared
to the CA-CDI group.
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CHAPTER V
Discussion
This study shows a significant difference in HCFA-CDI cases compared CA-CDI cases
where HCFA-CDI is more associated with antimicrobial exposure 14 days prior to a positive
stool collection and is more likely to have an underlying condition compared to the CA-CDI
group. Although there is little comparable data on trends of community-associated compared to
healthcare facility associated CDI in an urban setting, literature supports the findings that
antibiotics and underlying conditions are risk factors for CDI (Asha, et al; Henrich et al, 2009).
In addition, literature supports that healthcare facility associated infections are more likely to
have exposure to antibiotics than cases not exposed to a healthcare facility (Thomas, Stevenson,
& Riley, 2003).
The objective of this study was to describe C. difficile infection in the Atlanta population.
Based on literature review, it was predicted that healthcare facility associated CDI cases would
have greater associations of being on antibiotics 14 days prior to stool collection and have at
least one underlying condition. After conducting the analysis, this hypothesis was proven to be
correct. In addition, the rate of CDI infection based on 2010 incident cases, using the 2010
census data as the denominator, was calculated and determined to be 84 cases per 100,000
people.
The significance of antimicrobial associations was lower in the HCFA-CDI group than
the expected based on literature review regarding particular classes of antibiotics. Based on the
literature clindamycin, penicillins, cephalosporins, and fluoroquinoles are the most common
antibiotics associated with CDI (McDonald). Clindamycin has shown to be associated with CDI
due to clindamycin- resistant, toxigenic strains of C. difficile (Owens et al., 2008). In this
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analysis, clindamycin did not have a significant association to CDI. This also may be true since
clindamycin has been on the decline after being associated with so many C. difficile outbreaks
(Owens et al., 2008). This seems to be the case for cephalosporins, which were targeted as risk
factors for CDI and also related to outbreaks. Second and third generation cephalosporins were
identified as chief risk factors for a C. difficile outbreak in a Veterans Administration medical
center in New York (Owens et al., 2008). The literature supports cephalosporins as being a risk
factor for CDI, my results support the literature on cephalosporins have a significant association
of CDI. The literature also suggests that fluoroquinolones are associated with CDI outbreaks. C.
difficile is a hardy bacterium that has become resistant to these antimicrobial agents (Asha et al.,
2006). My results, however, supported a significant association of fluoroquinolone use in a
univariate analysis, but no significant association in a multivariate analysis. Metronidazole and
Vancomycin are antibiotics suggested for the treatment of CDI (Cohen et al., 2010). My results
indicate that Metronidazole and Vancomycin are significantly being used in cases that have CDI
14 days prior to stool collection. Moving forward it will be interesting to see how Metronidazole
and Vancomycin play a role in risk factors for CDI. The rates of antimicrobial resistant
infections are on the rise, since these two drugs are most commonly used as treatment for CDI,
public health precautions need to be considered to reduce the Metronidazole and Vancomycin
exposure to patients without C. difficile.
Of studies that have been conducted solely on healthcare facility onset CDI, the comorbidity of patients reflects similar findings to what this study presents, where chronic
conditions are associated with HCFA-CDI (Fawley, 2007). Underlying conditions found to be
associated with CDI in this study that differ from the current literature include cardiovascular
diseases, Neurological diseases, Tumors, Other Chronic diseases, and Diabetes. Underlying
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conditions found not to have a significant association with CDI that the literature suggested
would include Immunosuppressive disorders and gastrointestinal disorders. There are no current
hypotheses for why these two are not significant in this analysis.
Studies suggest than an increase in age puts patients at a higher risk of CDI than those younger
than 65 (Kutty et al., 2010). The results from this study support literature in that patients 65 and
older were more likely to have CDI than the younger age groups. In addition, the analysis
concluded that CDI cases older than 65 are significantly more likely to be HCFA compared to
CA.
This study represents an initial analysis on a specific population based on a surveillance
system put in place via the Centers for Disease Control and Prevention and the Emerging
Infections Program. This analysis can be used as a base line moving forward with surveillance
for the metropolitan Atlanta area regarding rates of C. difficile in a population and risk factors
associated with the infection. As the surveillance continues additional analysis can be conducted
to analyze severity of infection among case classifications. Furthermore, it would be interesting
to continue analysis on the antimicrobial associations with CDI in the Atlanta area, by continuing
surveillance and data collection for antibiotics taken 14 days prior to stool collection, trends can
be monitored to see if new resistance is forming based on the behavior of the clinical groups and
hospitals in Atlanta.
There were limitations to this study. To begin with, the sampling scheme made initial
analysis difficult due to the 1:3 sampling of all incident cases, then the additional 1:10 sample of
HCFO cases. Initially, comparing the three groups would have been interesting, but due to the
1:10 HCFO sample, that population was too small to conduct an accurate analysis. In addition,
proper weighting has not been established to make up for the small sample numbers. This study
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also does not adjust for the 1:3 sampling scheme, so this data is representative of a third of the
CDI population. In addition, the population analysis only consisted of those who had CDI,
therefore comparing CDI cases to CDI cases made analysis less straight forward for determining
the outcome variable.
The rate of C. difficile in the population being observed is higher than the rate of C.
difficile in the United States, 76 per 100,000 (Redelings et al., 2007). CDI seems to be increasing
over time which is either due to better testing methods, better surveillance, or an increase of
cases (Redelings et al., 2007). To prevent C. difficile in the population a number of actions can
be taken to reduce the incidence of CDI. First of all, hand washing and hygiene is very
important, especially in the healthcare facility environment or when exposed to someone who
has severe diarrhea. Secondly, reduce the amount of antibiotics that are prescribed in both
inpatient and outpatient settings. This can be done by assuring that antibiotics are given after
results of a positive culture for the assumed infection or disease. This leads in to the practice of
antimicrobial stewardship, which is the approach to preventing emergence of antimicrobial
resistance. According to a study by Fishman et al, 50% of antibiotics are prescribed
unnecessarily. This also includes better physician – patient interaction, where patients are
educated about the medications they are taking for their underlying conditions or antibiotics they
are on for specific infections. Combinations of these underlying conditions and antibiotics may
pose a higher risk for CDI. A third suggestion would be to conduct as a case control study, both
looking at CA-CDI cases matched to a community control, and HCFA-CDI cases matched to a
healthcare facility control. By conducting a case control interview, additional risk factors among
the groups will become clearer as to why some people are getting CDI and some are not.
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Conclusion
This study represents an analysis of one third of the CDI cases in the metro-Atlanta
population. Surveillance on C.difficile is important as the Antimicrobial Resistance Infections are
becoming more common. From this study we know that age greater than 65, being on antibiotics,
and having an underlying condition are risk factors for HCFA-CDI cases compared to CA-CDI
cases. The risk increases as patients are taking more than one antibiotic and have more than one
underlying condition (p< 0.0001). Therefore, it is important to reduce the risk of exposure of C.
difficile by using prevention methods discussed.
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Background
Clostridium Difficile (C. Diff) is an
anaerobic, spore-forming, toxigenic
bacteria that is the most commonly
recognized cause of infectious
nosocomial diarrhea and one of the
most common healthcare-associated
pathogens
 CDI = C. diff Infection
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Clinical Manifestation


Symptoms
 Asymptomatic to mild or moderate diarrhea

to fulminate or fatal colitis


Acquisition (a hypothesis)
Antimicrobial

Asymptomatic
C. difficile
colonization

C. difficile exposure

Hospitalization
Gerding DN, Discov Med. 2012; 13 (68):75-83
Slide Courtesy of Dale Gerding, Hines VA

C. difficile
infection
4
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Pathogenesis
1. Ingestion
of spores transmitted
from other patients
via the hands of healthcare
personnel and environment

3. Altered lower intestine flora
(due to antimicrobial use) allows
proliferation of
C. difficile in colon

4. Toxin A & B Production
leads to colon damage
+/- pseudomembrane

2. Germination into
growing (vegetative)
form

Sunenshine et al. Cleve Clin J Med. 2006;73:187-97.

Risk Factors: Antibiotics
The negative effect of antibiotics on the
gut flora is a risk for CDI
 96% of patients with CDI received
antimicrobials within the 14 days before
the onset of diarrhea and all had
received antimicrobial therapy within the
previous 3 months (Olsen et al)
 Most common antimicrobial exposures:
Clindamycin, penicillins, cephalosporins,
& fluoroquinolones (McDonald)
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Risk Factors: Underlying
Conditions
CDI was the most commonly isolated
bacterial cause of diarrhea in individuals
with HIV (Sanchez1992-2002).
 An increase in CDI was associated with
hospitalized children with severe medical
conditions such as IBD and
Immunosuppressive diseases (Nyland).
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Risk Factor: Age
Several studies suggest CDI is more
common in elderly people and old age
may promote susceptibility
 High incidence and increased mortality
among older patients attributed is to the
failure of these individuals to create an
effective immune response when first
exposed to C. difficile toxins.
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Healthcare Facility
Associated (HCFA) CDI
Hospitalization and exposure to
healthcare facilities is a risk factor for
acquisition for CDI (Miller et al).
 In 2006, in Ohio, 14,329 healthcare
Onset CDI cases were reported in 210
hospitals (Ohio Dept of Public Health).
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Community Associated (CA)
CDI
Populations now affected by CDI that would
normally be at low risk
 In a large UK study, 34% of the nonhospitalized CDI diagnosis in the community
had documented prior antibiotic use in
previous 90 days (Dial et al)
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Objectives & Hypothesis


Objective
 Examine the differences in antimicrobial use

and underlying conditions in CA vs HCFA
CDI.


H0
 There will be no difference in antimicrobial

use and underlying condition between the
CA and HCFA groups.

11

12

38

Case Identification
Identified through Clostridium difficile
Surveillance Program at the Georgia
Emerging Infections Program.
 Case Definition


 Positive Toxin Assay
 Age
 HD3
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Case Identification


HD3
 Pop ~ 3.7 million
○ Clayton
○ Cobb

○ Dekalb
○ Douglas
○ Fulton
○ Gwinnett
○ Newton
○ Rockdale
14
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Case Report Forms (CRFs)

15

Data Collected from CRFs
Variables of Interest
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CDI Case Classifications


Community Associated (CA)




Community Onset – Healthcare Facility
Associated (COHCFA)




Community onset without a documented overnight stay in a healthcare facility in the
12 weeks prior to initial positive C. diff stool

Community onset cases with an overnight stay at a healthcare facility in the 12
weeks prior to initial positive C. diff stool

Healthcare Facility Onset (HCFO)


Case with initial C. diff positive specimen collected greater or equal to 4 calendar
days after admission to a healthcare facility (acute care hospital, LTAC, LTCF, SNF)
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All CDI Incident Cases in HD3
Catchment
(September 1, 2009 –
April 30, 2011)
N = 5244
September 1, 2009 –
October 31, 2009
All Cases
N1= 453

November 1, 2009 –
April 30, 2011
1:3 Sampled
N2 = 1770

COHCFA1

CA1

HCFO2

COHCFA2

CA2

N=214

N=87

N= 134

N= 724

N= 326

N= 704

HCFO1
1:10
Sample
N=9

COHCFA1

CA1

HCFO2
1:10
Sample
N=56

COHCFA2

HCFO1

N=87

HCFO1+2
N=65

N= 134

COHCFA1+2
N=413

HCFA
N=477

N= 326

CA1
N= 134

Total Cases
N= 1314

CA2
N= 704

CA2
N= 704

CA1+2
N= 837
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Statistical Analysis


SAS Programming
 Univariate
 Logistic Regression

19

20
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Rate of CDI in HD3, 2010
3067 Incident cases in 2010 in a
population of 3,630,152 for an annual
rate of 84 cases per 100,000.
 Cases ranged in age from 1-102 (mean
56, median 63)
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Description of Cases, Sept
2009- April 2011
CA
n=837
(38%)
(col %)

CO-HCFA
n=413
(19%)
(col %)

HCFO
n=938
(43%)
(col %)

Total (%)

1-17
18-44
45-64
65+

208 (25)
179 (21)
237 (28)
214 (26)

30 (7)
65 (16)
103 (25)
215 (52)

15 (1.6)
81 (8.6)
231 (25)
611 (65)

253 (12)
325 (15)
568 (26)
1039 (47)

Male
Female

315 (38)
523 (62)

172 (42)
241 (58)

371 (40)
567 (60)

855 (39)
1330 (61)

308 (64)
151 (32)
19 (4)
9
351

228 (63)
114 (32)
18 (5)
6
47

516 (59)
344 (39)
15 (2)
12
51

1050 (48)
607 (28)
52 (2)
27 (1)
449 (21)

Age

Sex

Race/ Ethnicity
White/NH
Black/NH
Hispanic
Other
Unknown
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Description of Cases, Sept
2009- April 2011
Epiclass by Age
700

600

500

One-17
400

18-44
45-64

300

65+

200

100

0

CA

CO-HCFA

HCFO
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Description of Cases, Sept
2009- April 2011
Gender by Epiclass
600

500

400
Male
Female

300

200

100

0
CA

CO-HCFA

HCFO
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Description of Cases, Sept
2009- April 2011
Epiclass by Race/ Ethnicity
600

500

400

White/NH
Black/NH

300

Hispanic
200

100

0

CA

CO-HCFA

HCFO
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Univariate Descriptive
Analysis
CA (reference)
n=837

HCFA
n=477

p-value

Age
1-17 (reference)
18-44
45-64
65+

208
179
237
213

30
72
120
255

0.0013

Male (reference)
Female

314
523

198
280

0.5095

Race/ Ethnicity
White/NH (reference)
Black/NH
Hispanic

307
151
19

266
136
18

0.1979
0.0448

Sex
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Univariate Analysis
Antibiotics
None
Fluoroquinolones
Cephalosporins
Metronidazole
Vancomycin
Penicillins & Carbopenems
Clindamycin
Macroloids

CA
(%)
395 (47)
50 (7)
58 (7)
64 (8)
18 (2)
76 (9)
26 (3)
23 (3)

HCFA p-value
(%) (chi sq)
185 (39) 0.0032
100 (21) <0.0001
60 (13) 0.0006
55 (12)
52 (11) <0.0001
48 (10)
6 (1)
20 (4)
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Univariate Analysis
Underlying
Conditions
None
HIV/AIDS
Gastrointestinal
Cardiovascular
Neurological
Tumors
Other Chronic
Diabetes

CA
(%)
434 (52)
21 (3)
112 (13)
38 (5)
37 (4)
54 (6)
118 (14)
81 (10)

HCFA
(%)
73 (15)
25 (5)
57 (12)
106 (22)
84 (18)
47 (10)
211 (44)
129 (27)

p-value
(chi sq)
<0.0001
0.0096
<0.0001
<0.0001
<0.0001
<0.0001

Other Chronic includes: Chronic Pulmonary Disease, Chronic Liver
Disease, & Chronic Renal Insufficiency
28
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Risk Factor Index
Co-Morbidity Index
0
1
>2

CA
515
209
113

HCFA
98
171
208

Total
613
380
321

Antibiotic Use Index
0
1
>2

CA
557
202
78

HCFA
237
135
105

Total
794
337
183

29

Analysis: Logistic
Regression
Risk Factors
Antibiotics
None (reference)
Fluoroquinolones
Cephalosporins
Metronidazole
Vancomycin
Penicillins & Carbopenems
Clindamycin
Macroloids

CA (reference)

HCFA

p-value

395
27
23
41
13
60
25
17

185
44
28
41
32
35
5
15

0.0392
0.0041
0.0026
0.0008
0.0959
0.5603
0.1585
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Analysis: Logistic
Regression
Risk Factors
Underlying Conditions
None (reference)
HIV/AIDS
Gastrointestinal
Cardiovascular
Neurological
Tumor
Other Chronic
Diabetes

CA (reference)

HCFA

p-value

434
14
79
8
22
35
83
81

73
9
29
24
32
30
126
129

0.0448
0.0219
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
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Analysis: Odds Ratio
Risk Factor
Age

Odds Ratio (95% Wald CI)
1-17 (reference)
18-44
45-64
65+

1
1.7 (0.959, 2.896)
1.5 (0.877, 2.587)
2.4 (1.414, 4.193)

Male (reference)
Female

1
0.9 (0.682, 1.209)

White N/H (reference)
Black N/H
Hispanic

1
1.2 (0.889, 1.763)
2.2 (1.006, 4.996)

Sex

Race Ethnicity
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Analysis: Odds Ratio
Risk Factor
Antibiotics

Odds Ratio (95% Wald CI)
None (reference)
Vancomycin
Cephalosporin
Metronidazole
Fluoroquinolones
Macroloids
Penicillins & Carbopenems
Clindamycin

1
3.7 (1.716, 7.838)
2.8 (1.382, 5.576)
2.3 (1.347, 4.089)
1.9 (1.032, 3.497)
1.9 (0.785, 4.410)
1.6 (0.922, 2.704)
0.7 (0.246, 2.136)
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Analysis: Odds Ratio
Risk Factor
Underlying Conditions

Odds Ratio (95% Wald CI)
None (reference)
Cardiovascular
Other Chronic
Diabetes
Neurological
Tumors
HIV/AIDS
Gastrointestinal

1
10.9 (4.498, 26.805)
6.2 (4.068, 9.367)
5.4 (3.484, 8.251)
3.9 (2.006, 7.556)
3.6 (1.978, 6.469)
2.6 (1.022, 6.678)
1.9 (1.095, 3.200)

34

49

35

Discussion


Significant findings
 Age
○ Known= Age

 Antibiotics
○ Known= Fluoroquinolones, Clindamycin*,

Cephalosporins, Penicillins
○ Unknown= Metronidazole & Vancomycin
 Underlying Conditions
○ Known = HIV / Gastrointestinal*
○ Unknown = everything else
36
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Discussion


Clindamycin
 Dr. Ray, Grady HAI Study



Gastrointestinal Diseases
 Reasons for being insignificant
○ HCFO, 1:10 Sample – causing under-

representation.
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Strengths & Limitations


Strengths
 One of a few studies that analyzes a

population based surveillance data focusing
on community acquired infection.


Limitations
 The Sampling!
 First person to analyze the GA CDI data

 CA case data collection by Chart Reviews

only.
 Difficult to make findings generalizable.
38
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CDI Prevention


Hand washing and hygiene
 Especially in the healthcare facility

environment or when exposed to someone
with diarrhea
 Specific hand washing technique


Reduce Antibiotics that are prescribed in
both inpatient and outpatient settings
 According to Fishman 50% of antibiotics are

prescribed unnecessarily.
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Suggestions for Future
Studies
Conduct a Case – Control study (CDC
planning to start 2014)
 Collect additional information on CRF’s
including antibiotics taken 3 months
prior vs. 14 days prior to positive stool
collection (beginning with all 2012
cases- BAM!)
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I’m ready for your…

42

53

54

55

